BioPalace

BioPalace (BioPalace LLC) is a United States-based investment platform focused on biotech and healthcare royalty financing. According to its official website, the company describes itself as "a syndicate platform, not a fund," created to make overlooked biotech royalties investable. Its stated purpose is to underwrite, structure, and syndicate opportunities that are "too specialized for megacap funds but too valuable to remain illiquid." Rather than pooling capital into a blind fund, BioPalace presents curated royalty deals individually, allowing qualified investors to review and participate deal by deal. The platform's model centers on access and diligence. BioPalace advertises "curated high-quality royalty opportunities," an "independent rigorous diligence process," and no blind pool or fund commitment. Its audience is explicitly limited to qualified investors, and it invites parties who are "selling or advising on a royalty" to submit opportunities for review. This positions BioPalace at the intersection of specialty finance and life-sciences royalties, a niche where cash flows are tied to approved or late-stage therapies and where deal terms can include multi-year royalty streams. BioPalace also operates a research desk. Its website features a white paper, "The strategic guide to royalty financing in biopharma," described as a 42-page industry briefing with frameworks, comparables, and cautionary tales drawn from its own pipeline. The research content is presented as open access and free to download, serving both as thought leadership and as a funnel for investor and seller engagement. Featured offerings shown on the site illustrate the types of deals the platform markets: an ophthalmic therapy royalty approved in 2024 with a 12-year term and an asking amount of $8.4M; an oncology therapy royalty approved in 2022 with a 14-year term and an asking amount of $22M; and a cardiovascular therapy royalty in Phase III with a potential 16-year term and an indicative $3.6M. The site labels these as illustrative listings and states that full diligence packages are disclosed only to verified investors. As of the available evidence, BioPalace is a private, early-stage platform brand rather than a publicly listed company. Its public footprint is concentrated on its own website and a Wikidata entry. The company's positioning is specialized: it does not present itself as a general fund or asset manager, but as a deal-by-deal syndication venue for healthcare royalty opportunities.

BioPalace LLC is a United States-based platform brand focused on biotech and healthcare royalty financing. Public evidence about the company is limited to its official website and a Wikidata entry, and no founding date, founder, or ownership details are disclosed in the available sources. The company presents itself as a syndicate platform rather than an investment fund, built to make overlooked biotech royalties investable. The platform's operating model is deal-by-deal. According to its website, BioPalace curates high-quality royalty opportunities and provides qualified investors with access to individual deals, supported by an independent and rigorous diligence process. It explicitly states that it does not operate a blind pool and does not require fund commitments or capital deployment. This structure is intended to serve opportunities that are "too specialized for megacap funds but too valuable to remain illiquid." BioPalace also maintains a research desk. Its published white paper, "The strategic guide to royalty financing in biopharma," is described as a 42-page industry briefing covering frameworks, comparables, and cautionary tales from the company's own pipeline. The research is offered as open access and free to download, and it functions as both an educational resource and a channel for engaging investors and royalty sellers. The website features illustrative listings that indicate the types of deals BioPalace markets. These include an ophthalmic therapy royalty approved in 2024 with a 12-year term and an asking amount of $8.4M; an oncology therapy royalty approved in 2022 with a 14-year term and an asking amount of $22M; and a cardiovascular therapy royalty in Phase III with a potential 16-year term and an indicative $3.6M. The site notes that these are illustrative and that full diligence packages are disclosed only to verified investors. BioPalace invites parties who are selling or advising on a royalty to submit their opportunity for review, indicating a two-sided marketplace model connecting royalty holders with qualified investors. As of the available evidence, the company is private and its public footprint remains limited, with no disclosed headquarters, founding year, or executive team.

A syndicate platform, not a fund, providing qualified investors with curated, deal-by-deal access to overlooked biotech and healthcare royalties.

• Deal-by-deal biotech royalty syndication

  Curated biotech and healthcare royalty opportunities offered individually to qualified investors, with independent diligence and no blind pool.

• The strategic guide to royalty financing in biopharma (white paper)

  A 42-page industry briefing with frameworks, comparables, and cautionary tales from BioPalace's own pipeline, offered as a free download.

1. 1BioPalace — Invest in Biotech Royaltiesbiopalace.com
2. 2BioPalace LLCwikidata.org